[go: up one dir, main page]

WO2004035585A1 - Synthesis of zaleplon - Google Patents

Synthesis of zaleplon Download PDF

Info

Publication number
WO2004035585A1
WO2004035585A1 PCT/IN2002/000209 IN0200209W WO2004035585A1 WO 2004035585 A1 WO2004035585 A1 WO 2004035585A1 IN 0200209 W IN0200209 W IN 0200209W WO 2004035585 A1 WO2004035585 A1 WO 2004035585A1
Authority
WO
WIPO (PCT)
Prior art keywords
ethyl
cyanopyrazolo
formic acid
pyrimindin
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2002/000209
Other languages
French (fr)
Inventor
Renugadevi Gurusamy
Sankara Subramanian RAJARAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanmar Speciality Chemicals Ltd
Original Assignee
Sanmar Speciality Chemicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanmar Speciality Chemicals Ltd filed Critical Sanmar Speciality Chemicals Ltd
Priority to AU2002343201A priority Critical patent/AU2002343201A1/en
Priority to PCT/IN2002/000209 priority patent/WO2004035585A1/en
Publication of WO2004035585A1 publication Critical patent/WO2004035585A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Definitions

  • N-[3-(3-cyanopyrazolo [1,5-a] ⁇ yrimindin-7-yl) phenyl]-N-ethyl acetamide is an anxiolytic, antiepileptic sedative, hypnotic agent and skeletal muscle relaxant. This compound is being effectively used in curative and prophylactic pharmaceutical compositions against manifestations of the aforesaid symptoms.
  • US patent no.4,626,538 reports a process for preparing N-[3-(3- cyanopyrazolo [1,5-a] pyrimindin-7-yl) ⁇ henyl]-N-ethyl acetamide by reacting 3 -dimethylamino- 1 -(3-N-eth.y l-N-acety larninophenyl)-2- ⁇ ropen- 1 -one with 3 - aminopyrazole-4-carbonitrile in acetic acid medium.
  • EP patent no.776,898 Al and US patent no.5,714,607 report an improvement once the above referenced US patent no.4,626,538 resulting in better yield and purity of the final product. This improvement consists of adding water to acetic acid medium during the reaction.
  • Water and formic acid ratio to be used in this process may be about 20% to 80%. 2:2 v/v of water and formic acid mixture has also been found effective.
  • This invention relates to a process for synthesising N-[3-(3- cyanopyrazolo [1,5-a] pyrimindin-7-yl) phenyl]-N-ethyl acetamide which consists of reacting 3-dimethylamino-l-(3-N-ethyl-N-acetylaminophenyl(-2- propen-1-one with 3-amino pyrazole-4-carbonitrile in an aqueous formic and reaction medium and subsequently recovering the product from the reaction mixture in a known manner.
  • the product which crystallizes after the completion of the reaction is of 99% purity and may be filtered off and further purified by recrystallization.
  • This reaction is carried out in a reaction medium consisting of 10% to 60% of water and formic acid mixture. After heating the mixture for about 1 hour upto 70°C the reaction is completed. The title compound which is crystallized on cooling of the reaction mixture is filtered. The yield of the product is calculated to be 85% as compared with 76% overall yield obtained when the procedure reported in the US patent no.4,626,538 is used.
  • WO 02/12244 A2 has reported three crystalline polymorphic forms of N-[3-(3- cyanopyrazolo [1,5-a] pyrimindin-7-yl) phenyl]-N-ethyl acetamide - Form I, Form II and Form III.
  • the present invention corresponds to Form I, as evidenced by XRD and DSC data.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention relates to an improvement in the process of synthesizing N-[3-(3-cyanopyrazolo [1,5-a] pyrimindin-7-yl)phenyl]-N-ethyl acetamide. 3-dimethylamino-1-(3-N-ethyl-N-acetylaminophenyl)-2-propen-1-one is reacted with 3-aminopyrazole-4-carbonitrile in an aqueous formic acid reaction medium at a temperature ranging from 40 °C to 70 °C. This process results in better yields and higher purity of the final product.

Description

Synthesis of Zaleplon
Technical field:
N-[3-(3-cyanopyrazolo [1,5-a] ρyrimindin-7-yl) phenyl]-N-ethyl acetamide is an anxiolytic, antiepileptic sedative, hypnotic agent and skeletal muscle relaxant. This compound is being effectively used in curative and prophylactic pharmaceutical compositions against manifestations of the aforesaid symptoms.
Background Art:
US patent no.4,626,538 reports a process for preparing N-[3-(3- cyanopyrazolo [1,5-a] pyrimindin-7-yl) ρhenyl]-N-ethyl acetamide by reacting 3 -dimethylamino- 1 -(3-N-eth.y l-N-acety larninophenyl)-2-ρropen- 1 -one with 3 - aminopyrazole-4-carbonitrile in acetic acid medium.
EP patent no.776,898 Al and US patent no.5,714,607 report an improvement once the above referenced US patent no.4,626,538 resulting in better yield and purity of the final product. This improvement consists of adding water to acetic acid medium during the reaction.
Disclosure of the invention:
It is the object of this invention to provide a one-pot process for the preparation of N-[3-(3-cyanopyrazolo [1,5-a] ρyrimindin-7-yl) phenyι]-N-efhyl acetamide resulting in hitherto unreported yield and purity. It has now been found that the yield and purity of N-[3-(3- cyanopyrazolo [1,5-a] pyrimindin-7-yl) phenyl]-N-ethyl acetamide can be enhanced by carrying out the reaction of 3-dimethylamino-l-(3-N-ethyl-N- acetylaminophenyl)-2-propen-l-one with 3-amino pyrazole-4-carbonitrile in the presence of aqueous formic acid instead of aqueous acetic acid as reported in prior art literature. Formic acid is odourless, environment friendly and leads to a cost-effective process for manufacturing the title compound.
Yet another advantage of using aqueous formic acid instead of acetic acid the invented process is that the time for completion of the reaction is decreased from 3.5 hours to about 1 hr. Further, it is noticed that the reaction temperature is decreased to about 50°C as against the reflux temperature of about 90°C in the prior art. The product crystallizes out in the reaction medium itself on completion of the reaction, thus avoiding multiple process steps. The overall advantage of this improved process are better yields, high purity, reduced reaction time and cost effectiveness. Since crystallization is in situ, this improved process may also be considered as a one-pot process. In the known prior process, the reaction is carried out as the reflux temperature of acetic acid which results in the formation of contaminating side products, which is also avoided in this improved process.
Water and formic acid ratio to be used in this process may be about 20% to 80%. 2:2 v/v of water and formic acid mixture has also been found effective.
This invention relates to a process for synthesising N-[3-(3- cyanopyrazolo [1,5-a] pyrimindin-7-yl) phenyl]-N-ethyl acetamide which consists of reacting 3-dimethylamino-l-(3-N-ethyl-N-acetylaminophenyl(-2- propen-1-one with 3-amino pyrazole-4-carbonitrile in an aqueous formic and reaction medium and subsequently recovering the product from the reaction mixture in a known manner. The product which crystallizes after the completion of the reaction is of 99% purity and may be filtered off and further purified by recrystallization.
The reaction scheme shown below shows the process of the present invention.
SCHEME 1
Formic acid Water
Figure imgf000004_0001
Figure imgf000004_0002
This reaction is carried out in a reaction medium consisting of 10% to 60% of water and formic acid mixture. After heating the mixture for about 1 hour upto 70°C the reaction is completed. The title compound which is crystallized on cooling of the reaction mixture is filtered. The yield of the product is calculated to be 85% as compared with 76% overall yield obtained when the procedure reported in the US patent no.4,626,538 is used.
WO 02/12244 A2 has reported three crystalline polymorphic forms of N-[3-(3- cyanopyrazolo [1,5-a] pyrimindin-7-yl) phenyl]-N-ethyl acetamide - Form I, Form II and Form III. The present invention corresponds to Form I, as evidenced by XRD and DSC data.
The invention will now be described with reference to specific embodiments. EXAMPLES
EXAMPLE 1:
N-[3-(3-cyanopyrazolo [1,5-al pyrimindin-7-yr) phenyll-N-ethyl acetamide
A mixture of 5g of 3-dimethylamino-l-(3-N-ethyl-N- acetylaminophenyl)-2-propen-l-one and 2.1g of 3-aminopyrazole-4- carbonitrile in 15 ml of formic acid and 10 ml water is warmed to 50°C. After about 1 hour the reaction mixture is cooled to a temperature of about 0 to 5°C and the crystalline product formed is filtered, washed with water and dried at 60°C. The product is obtained in 78% yield and the purity by HPLC is 99.61%.
EXAMPLE 2:
N-[3-(3-cyanopyrazolo [1,5-al pyrimindin-7-yl) phenyll-N-ethyl acetamide
A mixture of 5g of 3-dimethylamino-l-(3-N-ethyl-N- acetylaminophenyl)-2-propen-l-one and 2.1g of 3-aminopyrazole-4- carbonitrile in 15 ml of formic acid and 45 ml water is warmed to 50°C. After about 1 hour the reaction mixture is cooled to a temperature of about 0 to 5°C and the crystalline product formed is filtered, washed with water and dried at 60°C. The product is obtained in 70% yield and the purity by HPLC is 99.80%. EXAMPLE 3:
N-[3-(3-cyanopyrazolo [1,5-a] pyrimindin-7-vD phenyll-N-ethyl acetamide
A mixture of 5g of 3-dimethylamino-l-(3-N-ethyl-N- acetylaminophenyl)-2-propen-l-one and 2.1g of 3-aminopyrazole-4- carbonitrile in 10 ml of formic acid and 20 ml water is warmed to 50°C. After about 1 hour the reaction mixture is cooled to a temperature of about 0 to 5°C and the crystalline product formed is filtered, washed with water and dried at 60°C. The product is obtained in 85% yield and the purity by HPLC is 99.72%.
EXAMPLE 4:
N-r3-(3-cyanopyrazolo [1,5-a] pyrimindin-7-vD phenyll-N-ethyl acetamide
A mixture of 5g of 3-dimethylamino-l-(3-N-ethyl-N- acetylaminophenyl)-2-propen-l-one and 2.1g of 3-aminopyrazole-4- carbonitrile in 25 ml of formic acid and 25 ml water is warmed to 50°C. After about 1 hour the reaction mixture is cooled to a temperature of about 0 to 5°C and the crystalline product formed is filtered, washed with water and dried at 60°C. The product is obtained in 70% yield and the purity by HPLC is 99.51%.
EXAMPLE 5:
N-[3-(3-cvanopyrazolo [1,5-a] pyrimindin-7-yl) phenyll-N-ethyl acetamide
A mixture of 5g of 3-dimethylamino-l-(3-N-ethyl-N- acetylaminophenyl)-2-propen-l-one and 2.1g of 3-aminopyrazole-4- carbonitrile in 5 ml of formic acid and 10 ml water is warmed to 50°C. After about 1 hour the reaction mixture is cooled to a temperature of about 0 to 5°C and the crystalline product formed is filtered, washed with water and dried at 60°C. The product is obtained in 80% yield and the purity by HPLC is 99.65%.
TABLE 1:
The following table summarizes the various reaction conditions followed in the process of formation of N-[3-(3-cyanopyrazolo [1,5-a] pyrimindin-7-yl) phenyl]-N-ethyl acetamide.
Figure imgf000007_0001

Claims

CLAIMS:
1. A process for synthesizing_N-[3-(3-cyanopyrazolo [1,5-a] pyrimindin-7- yl) phenyl]-N-ethyl acetamide which consists of reacting 3- dimethylamino-l-(3-N-ethyl-N-acetylaminophenyl)-2-propen-l-one with 3-aminopyrazole-4-carbonitrile in an aqueous formic acid reaction medium and subsequently recovering the product from the reaction mixture in a known manner.
2. The process as claimed in claim 1 wherein said reaction is carried out in aqueous formic acid medium of about 20% to about 80% v/v of water and formic acid.
3. The process as claimed in claims 1 and 2 wherein the reaction mixture is heated to 40°C to 60°C for about 1 to 2 hours.
4. The process as claimed in claim 3 wherein said reaction mixture is cooled and the crystallized product filtered off.
5. The process as claimed in claim 4 wherein said product obtained after filtration is further purified.
6. A process for synthesizing N-[3-(3-cyanopyrazolo [1,5-a] pyrimindin-7- yl) phenyl]-N-ethyl acetamide substantially as herein described with reference to the examples.
7. N-[3-(3-cyanopyrazolo [1,5-a] pyrimindin-7-yl) phenyl]-N-ethyl acetamide whenever prepared by a process as claimed in claims 1 to 6.
PCT/IN2002/000209 2002-10-16 2002-10-16 Synthesis of zaleplon Ceased WO2004035585A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002343201A AU2002343201A1 (en) 2002-10-16 2002-10-16 Synthesis of zaleplon
PCT/IN2002/000209 WO2004035585A1 (en) 2002-10-16 2002-10-16 Synthesis of zaleplon

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2002/000209 WO2004035585A1 (en) 2002-10-16 2002-10-16 Synthesis of zaleplon

Publications (1)

Publication Number Publication Date
WO2004035585A1 true WO2004035585A1 (en) 2004-04-29

Family

ID=32104608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2002/000209 Ceased WO2004035585A1 (en) 2002-10-16 2002-10-16 Synthesis of zaleplon

Country Status (2)

Country Link
AU (1) AU2002343201A1 (en)
WO (1) WO2004035585A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072527A1 (en) * 2000-08-03 2002-06-13 Ssci, Inc. Polymorphs of zaleplon and methods for the preparation thereof
US20030040522A1 (en) * 2001-06-12 2003-02-27 Ferenc Korodi Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072527A1 (en) * 2000-08-03 2002-06-13 Ssci, Inc. Polymorphs of zaleplon and methods for the preparation thereof
US20030040522A1 (en) * 2001-06-12 2003-02-27 Ferenc Korodi Process for the production of N-[3-(3-cyanopyrazolo[1,5-a] pyrimidin-7-yl) phenyl]-N-ethylacetamide (zaleplon)

Also Published As

Publication number Publication date
AU2002343201A1 (en) 2004-05-04

Similar Documents

Publication Publication Date Title
US5714607A (en) Process improvement in the synthesis of N- 3-(3-cyano-pyrazolo 1,5-a!pyrimidin-7-yl)phenyl!-N-ethylacetamide
KR101609898B1 (en) A process for preparing r-beta-amino phenylbutyric acid derivatives
JP2003517484A (en) Method for producing pure citalopram
MX2015004764A (en) Compounds useful in the synthesis of benzamide compounds.
CN116715663A (en) A kind of preparation method of fenelidone and its intermediates
US6335463B1 (en) Method of manufacturing sertindole
EP2608791B1 (en) A process for the preparation of imatinib base
HUP0200839A2 (en) Novel synthesis and crystallization of piperazine ring-containing compounds and pharmaceutical compositions containing them
JP2019108351A (en) Methods for producing molindone and its salts
WO2004035585A1 (en) Synthesis of zaleplon
US20080227980A1 (en) Preparation of a 7H-Pyrrolo [2,3-D] Pyrimidine Derivative
JP2002520313A (en) Synthesis of compounds useful for the production of ketorolac
KR101248123B1 (en) Zaleplon synthesis
JP4790901B2 (en) Process for producing 4-amino-5-cyanoimidazole derivative and its intermediate
JP2681873B2 (en) Method for producing tizanidine
HU225667B1 (en) Method for producing high-purity 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine
JPS60208963A (en) Manufacture of diaminopyridine derivative
JP4699582B2 (en) Method for producing 1H-4 (5) -aminoimidazole-5 (4) -carboxamide
WO2007094007A1 (en) An improved process for the preparation of entacapone
TW201121954A (en) Process for the preparation of 5-(2-amino-pyrimidin-4-yl)-2-aryl-1H-pyrrole-3-carboxamides
TWI453182B (en) Process for the preparation of (r)-β-amino-phenyl butyric acid derivatives
CN100395246C (en) Process for the manufacture of folic acid antagonists and intermediates thereof
KR100850558B1 (en) Efficient preparation of atorvastatin
JP2010538971A (en) Method for producing valsartan salt effective for producing valsartan
JP2001302609A (en) Method for producing n-(2-amino-1,2-dicyanovinyl)formic acid derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP